Advertisement
Singapore markets closed

  • Straits Times Index

    3,296.89
    +4.20 (+0.13%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • Dow

    37,903.29
    +87.37 (+0.23%)
     

  • Nasdaq

    15,605.48
    -52.34 (-0.33%)
     

  • Bitcoin USD

    58,667.61
    +932.84 (+1.62%)
     

  • CMC Crypto 200

    1,268.86
    -1.88 (-0.15%)
     

  • FTSE 100

    8,155.60
    +34.36 (+0.42%)
     

  • Gold

    2,304.10
    -6.90 (-0.30%)
     

  • Crude Oil

    79.18
    +0.18 (+0.23%)
     

  • 10-Yr Bond

    4.6280
    +0.0330 (+0.72%)
     

  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     

  • Hang Seng

    18,207.13
    +444.10 (+2.50%)
     

  • FTSE Bursa Malaysia

    1,580.30
    +4.33 (+0.27%)
     

  • Jakarta Composite Index

    7,117.42
    -116.77 (-1.61%)
     

  • PSE Index

    6,646.55
    -53.94 (-0.81%)
     

‘Still in Talks With Indian Govt’, Says J&J Regarding COVID Vaccine Approval

The Quint
Updated ·2-min read

United States (US) based pharmaceutical company Johnson & Johnson said on Monday, 2 August, that it was still in talks with the Indian government over its COVID-19 vaccine, Janssen, after India's drug regulator Central Drugs Standard Control Organisation (CDSCO) announced that J&J had withdrawn its proposal seeking accelerated approval for local trials, news agency Reuters reported.

Moreover, in May, India had scrapped local trials for 'well-established' foreign coronavirus vaccines in order to hasten vaccination rollouts to fight a second wave of infections.

The supposed proposal withdrawal comes while India tackles legal challenges with manufacturers over indemnity issues. Union Minister of State for Health and Family Welfare Bharati Pravin Pawar was quoted by Reuters as saying:

ADVERTISEMENT

""This team is in continuous dialogue with Pfizer, Moderna and Johnson and Johnson to discuss and address various issues including the issue of indemnity."" -

Also Read: Indian Govt’s Indemnity ‘Doublespeak’: Why COVAXIN But Not Others?

Previously, in April, Johnson and Johnson had said that it was seeking an approval to conduct a bridging clinical study of it's COVID-19 vaccine candidate in India. During that period, however, trials were paused in the United States over reports of rare blood clots.

According to Reuters, as of 31 July, Johnson and Johnson is yet to request a full approval for its shot with the United States FDA.

As of 28 July, around 10 percent of India's adult population had been inoculated with both doses, with 47 percent having received at least one jab.

(With inputs from Reuters)

Also Read: Johnson & Johnson To Stop Selling Opioids, Enters $230 Mn Deal

. Read more on COVID-19 by The Quint.Day 11, Tokyo Olympics LIVE: Belgium leading 3-2 against India‘Still in Talks With Indian Govt’, Says J&J Regarding COVID Vaccine Approval . Read more on COVID-19 by The Quint.